These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28056160)

  • 21. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.
    Liang Q; Chen Y; Yu K; Chen C; Zhang S; Wang A; Wang W; Wu H; Liu X; Wang B; Wang L; Hu Z; Wang W; Ren T; Zhang S; Liu Q; Yun CH; Liu J
    Eur J Med Chem; 2017 May; 131():107-125. PubMed ID: 28315597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
    Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
    J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
    Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
    J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
    Zhao D; Huang S; Qu M; Wang C; Liu Z; Li Z; Peng J; Liu K; Li Y; Ma X; Shu X
    Eur J Med Chem; 2017 Jan; 126():444-455. PubMed ID: 27912175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinase Crystal Miner: A Powerful Approach to Repurposing 3D Hinge Binding Fragments and Its Application to Finding Novel Bruton Tyrosine Kinase Inhibitors.
    Mukherjee P; Bentzien J; Bosanac T; Mao W; Burke M; Muegge I
    J Chem Inf Model; 2017 Sep; 57(9):2152-2160. PubMed ID: 28792217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors.
    Zhao X; Xin M; Huang W; Ren Y; Jin Q; Tang F; Jiang H; Wang Y; Yang J; Mo S; Xiang H
    Bioorg Med Chem; 2015 Jan; 23(2):348-64. PubMed ID: 25515957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
    Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.
    Kuglstatter A; Wong A; Tsing S; Lee SW; Lou Y; Villaseñor AG; Bradshaw JM; Shaw D; Barnett JW; Browner MF
    Protein Sci; 2011 Feb; 20(2):428-36. PubMed ID: 21280133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.
    Boga SB; Alhassan AB; Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Yu Y; Anand R; Liu S; Yang C; Wu H; Cai J; Zhu H; Desai J; Maloney K; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Knemeyer I; Garlisi CG; Bays N; Stivers P; Brandish PE; Hicks A; Cooper A; Kim RM; Kozlowski JA
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3939-3943. PubMed ID: 28720503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation mechanism and steady state kinetics of Bruton's tyrosine kinase.
    Dinh M; Grunberger D; Ho H; Tsing SY; Shaw D; Lee S; Barnett J; Hill RJ; Swinney DC; Bradshaw JM
    J Biol Chem; 2007 Mar; 282(12):8768-76. PubMed ID: 17264076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
    Watterson SH; De Lucca GV; Shi Q; Langevine CM; Liu Q; Batt DG; Beaudoin Bertrand M; Gong H; Dai J; Yip S; Li P; Sun D; Wu DR; Wang C; Zhang Y; Traeger SC; Pattoli MA; Skala S; Cheng L; Obermeier MT; Vickery R; Discenza LN; D'Arienzo CJ; Zhang Y; Heimrich E; Gillooly KM; Taylor TL; Pulicicchio C; McIntyre KW; Galella MA; Tebben AJ; Muckelbauer JK; Chang C; Rampulla R; Mathur A; Salter-Cid L; Barrish JC; Carter PH; Fura A; Burke JR; Tino JA
    J Med Chem; 2016 Oct; 59(19):9173-9200. PubMed ID: 27583770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
    Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
    Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase.
    Kawahata W; Asami T; Fujii I; Sawa M
    Bioorg Med Chem Lett; 2015; 25(10):2141-5. PubMed ID: 25843639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel BTK inhibitors with carboxylic acids.
    Gao X; Wang J; Liu J; Guiadeen D; Krikorian A; Boga SB; Alhassan AB; Selyutin O; Yu W; Yu Y; Anand R; Liu S; Yang C; Wu H; Cai J; Cooper A; Zhu H; Maloney K; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Zhang-Hoover J; Knemeyer I; Garlisi CG; Bays N; Stivers P; Brandish PE; Hicks A; Kim R; Kozlowski JA
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1471-1477. PubMed ID: 28254166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold.
    Lou Y; Sweeney ZK; Kuglstatter A; Davis D; Goldstein DM; Han X; Hong J; Kocer B; Kondru RK; Litman R; McIntosh J; Sarma K; Suh J; Taygerly J; Owens TD
    Bioorg Med Chem Lett; 2015 Jan; 25(2):367-71. PubMed ID: 25466710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.
    Lin L; Czerwinski R; Kelleher K; Siegel MM; Wu P; Kriz R; Aulabaugh A; Stahl M
    Biochemistry; 2009 Mar; 48(9):2021-32. PubMed ID: 19206206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK).
    Lou Y; Lopez F; Jiang Y; Han X; Brotherton C; Billedeau R; Gabriel S; Gleason S; Goldstein DM; Hilgenkamp R; Kocer B; Orzechowski L; Tan J; Wovkulich P; Wen B; Fry D; Di Lello P; Chen L; Zhang FJ; Fretland J; Nangia A; Yang T; Owens TD
    Bioorg Med Chem Lett; 2017 Feb; 27(3):632-635. PubMed ID: 28025004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.